CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

Thinkhat attends the Precision Medicine World Conference (PMWC) and unveils the first of its AI-driven healthcare and life science (HLS) p ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

The recipient was Tim Andrews, a 66-year-old New Hampshire resident who had end-stage kidney disease and was on dialysis for ...